Data Re-Use Across Processes and Sites: Governance


Published on 09/12/2025

Data Re-Use Across Processes and Sites: Governance

Post updated on 02/06/2026

The pharmaceutical industry is increasingly recognizing the value of data re-use across various processes and sites to enhance efficiency and compliance. In the context of extractables and leachables (E&L), understanding the governance framework surrounding data re-use is essential for mitigating risks and ensuring regulatory compliance, particularly under the guidelines issued by organizations such as the US FDA, EMA, and MHRA. This tutorial aims to provide a step-by-step guide for pharmaceutical professionals on how to govern data re-use effectively in relation to filters, single-use systems, and packaging qualification.

Understanding Extractables and Leachables

Extractables and leachables (E&L) are critical considerations in the pharmaceutical industry, particularly in relation to the safety and efficacy of drug products. Extractables refer to compounds that can be extracted from a material under controlled conditions, while leachables are compounds that can migrate into the drug product during storage or use. Understanding E&L is crucial for ensuring patient safety, as these compounds can potentially interact with the drug formulation.

The Need for E&L Risk Assessment

Conducting an E&L risk assessment is vital for identifying the risks posed by different materials used in drug packaging and delivery systems. Factors influencing the risk assessment include the type of material, the extraction conditions, and the specific drug formulation. The FDA and EMA provide guidelines on conducting these assessments, emphasizing the importance of scientifically justified approaches.

  • Regulatory Guidelines: Familiarize yourself with the relevant regulations, including the FDA’s guidance document on E&L testing.
  • Material Type: Assess the materials involved in packaging and delivery to identify potential E&L compounds.
  • Extraction Conditions: Define the extraction conditions that closely simulate real-life usage to ensure relevant data collection.
  • Compounding Considerations: Account for any drug-specific factors that may influence E&L behavior.

Application of Analytical Evaluation Thresholds (AET) and Dose-Based Thresholds (DBT)

One of the pivotal concepts in E&L assessment is the determination of Analytical Evaluation Thresholds (AET) and Dose-Based Thresholds (DBT). These thresholds establish acceptable limits for leachables, guiding the analytical laboratories on which compounds should undergo rigorous testing.

AET/DBT Calculation Process

Calculating AET and DBT involves various parameters that need to be considered. The following steps outline the process:

  1. Identify the Drug Product Characteristics: Consider the intended use, dosage form, and patient population.
  2. Determine the Daily Dose (DD): The DD is critical for calculating the DBT. It is typically derived from the therapeutic dosage information available for the specific drug.
  3. AET Calculation: Calculate AET based on the toxicity of the leachables using toxicological data.
  4. Establish DBT: Use the calculated AET along with the DD to establish a safe exposure limit.
  5. Documentation: Ensure that all calculations are thoroughly documented for future reference and inspection, adhering to QA standards.

Container Closure Integrity (CCI) Testing

Container closure integrity (CCI) is an essential aspect of pharmaceutical packaging validation. It ensures that the drug product is protected from environmental contaminants, such as moisture, oxygen, and microbiological contamination. The USP has outlined specific guidelines that need to be adhered to, particularly for parenteral products.

Importances of Conducting CCI Testing

  • Regulatory Compliance: Compliance with CCI testing guidelines is essential for meeting the standards set by regulatory bodies.
  • Quality Assurance: CCI testing protects the integrity of the drug product, which is crucial for its effectiveness.
  • Marketability: Ensure the packaging meets customer safety expectations, facilitating informed market entry.

Common Methods for CCI Testing

Various methods can be employed to conduct CCI testing:

  1. Positive Pressure Leak Test: Involves subjecting the container to positive pressure and monitoring for integrity.
  2. Nitrogen Purging Technique: Utilizes nitrogen to purge the container, followed by a pressure decay test.
  3. Vacuum Decay Test: This method assesses leaks by creating a vacuum inside the container and measuring pressure over time.

Validation of Single-Use Systems

Single-use systems (SUS) have gained significant traction in the pharmaceutical industry due to their convenience and reduced risk of cross-contamination. Validating these systems requires a comprehensive understanding of their lifecycle and operational parameters.

Steps to Validate Single-Use Systems

  1. Process Design Review: Begin with a comprehensive review of the proposed process utilizing SUS to ensure it meets operational and regulatory standards.
  2. Material Compatibility Studies: Conduct compatibility studies to assess how the system material interacts with the drug product.
  3. Performance Qualification: Perform performance qualification tests to ensure the system operates effectively under specified conditions.
  4. CQI and CCI Testing: Incorporate Container Quality and Integrity testing protocols to verify the reliability of the single-use systems.
  5. Documentation and Record Keeping: Maintain detailed records to fulfill both internal quality management and regulatory compliance needs.

Governance Framework for Data Re-Use

Establishing a governance framework for data re-use is essential for ensuring compliance with FDA, EMA, and MHRA guidelines. A structured approach incorporates best practices that support quality management principles.

Key Elements of an Effective Governance Framework

  • Policy Development: Develop clear policies that delineate data governance roles and responsibilities.
  • Data Quality Management: Implement procedures for data integrity, accuracy, and reliability.
  • Risk Management: Continuously evaluate and mitigate risks associated with data re-use, focusing on E&L implications.
  • Training and Education: Provide ongoing training for staff on best practices in data governance and E&L compliance.
  • Continuous Monitoring: Establish a system for continuous monitoring of compliance with governance policies.

Conclusion

In conclusion, effective governance for data re-use across processes and sites is paramount in the pharmaceutical industry, especially concerning extractables and leachables. By understanding E&L risk assessments, calculating Analytical Evaluation Thresholds and Dose-Based Thresholds, and implementing robust container closure integrity testing, pharmaceutical professionals can ensure regulatory compliance and enhance product safety. Lastly, a well-defined governance framework will empower organizations to leverage data effectively while maintaining compliance with US, UK, and EU regulatory requirements.